New antiepileptic drugs
著者
書誌事項
New antiepileptic drugs
（Epilepsy research. Supplement, Supplement ; no. 3）
Elsevier , Sole distributors for the USA and Canada, Elsevier Science Pub. Co., 1991
大学図書館所蔵 件 / 全2件
-
該当する所蔵館はありません
- すべての絞り込み条件を解除する
注記
Includes bibliographical references
内容説明・目次
内容説明
The pharmacological fight against epilepsy began many centuries ago when Hippocrates discovered that the cause of epilepsy is natural, as opposed to supernatural and, as a consequence, must be treated with a natural remedy. Even though science has significantly progressed since that era, the challenge to find remedies for epilepsy is ever present. The aim of this particular volume is to offer an up-to-date review of the most recent advances in antiepileptic drug development, considered from various viewpoints: (i) general, by taking into account the size of refractory epilepsy and its related problems; (ii) experimental, by exploring the mechanisms of epileptogenesis and the possiblility of influencing it through drugs, and (iii) clinical, by describing the results obtained with compounds currently at an advanced stage of testing.
目次
Preface (F. Pisani, E. Perucca, G. Avanzini, A. Richens). Introduction (R. Di Perri, D. Janz). General Aspects. Chapter 1. Mental deterioration in a population with intractable epilepsy (H. Meinardi, A.M. Beun, B. Aldenkamp, B. Nunes, M. Engelsman, E. Forceville). Chapter 2. The influence of antiepileptic drugs on the natural history of epilepsy (E.H. Reynolds). Experimental Aspects. Chapter 3. Rational basis for the development of new antiepileptic drugs (R. Mutani, R. Cantello, M. Gianelli, D. Bettucci). Chapter 4. Genetic animal models for generalized non convulsive epilepsies and new antiepileptic drugs (G. Avanzini, C. Marescaux). Chapter 5. Excitatory amino acids in epilepsy and novel anti-epileptic drugs (A.G. Chapman, B.S. Meldrum). Chapter 6. Anticonvulsant activity of some calcium antagonists in genetically epilepsy prone rats (G. De Sarro, G.R. Trimarchi, R. Federico, A. De Sarro). Chapter 7. The brain distribution of old and new antiepileptic drugs (F. Monaco, G. Sechi). Clinical Aspects. Chapter 8. Evaluation of clinical efficacy in antiepileptic drugs trials (D. Schmidt). Chapter 9. Pharmacokinetics and interactions of the new antiepileptic drugs (E. Perucca, F. Pisani). Chapter 10. The efficacy and safety of new antiepileptic drugs (A. Richens). The New Antiepileptic Drugs. Chapter 11. Eterobarb (K.D. Wolter). Chapter 12. Felbamate (R. Duane Sofia, L. Kramer, J.L. Perhach, A. Rosenberg). Chapter 13. Gabapentin (M. Foot, J. Wallace). Chapter 14. Lamotrigine (A.W.C. Yuen). Chapter 15. Loreclezole (F. De Beukelaar, L. Tritsmans). Chapter 16. Losigamone (U. Stein, K. Klessing, S.S. Chatterjee). Chapter 17. Oxcarbazepine (P. Klosterskov-Jensen, L. Gram, M. Schmutz). Chapter 18. Ralitoline (H. Anhut, G. Satzinger, A. Von Hodenberg). Chapter 19. Remacemide (K.T. Muir, G.C. Palmer). Chapter 20. Stiripentol (J.C. Vincent). Chapter 21. Tiagabine (M.W. Pierce, P.D. Suzdak, L.E. Gustavson, H.B. Mengel, J.F. McKelvy, T. Mant). Chapter 22. Vigabatrin (J.P. Mumford, P.J. Lewis). Chapter 23. Zonisamide (M. Seino, H. Miyazaki, T. Ito). Recent Clinical Trials. Chapter 24. Kinetics, metabolism and effects of carbamazepine-10,11-epoxide in man (T. Tomson, L. Bertilsson). Chapter 25. Gabapentin (D. Chadwick). Chapter 26. Lamotrigine in refractory epilepsy: a long-term open study (F. Pisani, M. Russo, R. Trio, C. Artesi, A. Fazio, G. Oteri, R. Di Perri). Chapter 27. Vigabatrin (R. Michelucci, C.A. Tassinari).
「Nielsen BookData」 より